

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF NATIONAL CENTRALIZED MEDICINES PROCUREMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s new product Ropivacaine Hydrochloride Injection in form of ampoule and Fluconazole & Sodium Chloride Injection were awarded the third place and the second place respectively in the tender results of National Centralized Medicines Procurement (全國藥品集中採購) in the PRC on 23 June 2021.

According to the tendering arrangement of National Centralized Medicines Procurement, the Group’s Ropivacaine Hydrochloride Injection in form of ampoule will be exclusively supplied to 5 provinces including Shandong, Anhui, Yunnan, Inner Mongolia and Hainan, and Fluconazole & Sodium Chloride Injection will be exclusively supplied to 10 provinces including Guangdong, Jiangsu, Shandong, Guangxi, Hebei, Fujian, Heilongjiang, Inner Mongolia, Tianjin and Ningxia. The Board expects that the tender results will be beneficial to rapid market development, formation of large-scale sales and increase in market share of the relevant products, and will bring a positive result on the Group’s sales in the future.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
Company Secretary

Hong Kong, 24 June 2021

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*